Tavexia Lifecare Ltd

Tavexia Lifecare Limited, formerly known as Sattva Sukun Lifecare Limited, will hold a board meeting on Wednesday, November 4, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026, and to discuss a proposal for fund raising by way of a preferential issue, right issue, or other mode.

Tavexia Lifecare Limited, formerly known as Sattva Sukun Lifecare Limited, informed the BSE Limited that it is submitting a certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and participants) Regulations, 2018, received from Niche Technologies Pvt. Ltd., the company’s Registrar and Share Transfer Agent, for the quarter ended September 30, 2026.

Tavexia Lifecare Limited, formerly Sattva Sukun Lifecare Limited, will hold a board meeting on Wednesday, October 7, 2026, to further discuss and deliberate upon the proposed acquisition of up to 60% of the equity share capital of Meyonex Pharmaceuticals Limited, an unlisted public company with CIN: U74120MH2015PLC261024, following a previous board meeting on September 7, 2026, where the acquisition proposal was approved. The company also announced that the trading window for its securities was closed from September 30, 2026, until 48 hours after the board meeting for the approval of the un-audited financial results for the half year ended September 30, 2026.

Tavexia Lifecare Limited, formerly Sattva Sukun Lifecare Limited, informed the BSE Limited that the trading window for dealing in shares of the company will be closed for all directors, promoters, designated persons, and their immediate relatives, effective October 1, 2026, until 48 hours after the announcement of unaudited financial results for the quarter and half year ended September 30, 2026.

Tavexia Lifecare Limited, formerly Sattva Sukun Lifecare Limited, has informed the BSE Ltd. that its book closure will be from September 24, 2026, to September 30, 2026, both dates inclusive, for the purpose of the 46th Annual General Meeting.

Tavexia Lifecare Limited, formerly Sattva Sukun Lifecare, announced several key decisions following a board meeting held September 7, 2026. The company authorized the exploration of acquiring shares of Meyonex Pharmaceuticals Limited, a pharmaceutical company with a registered address in Palghar, Maharashtra, and an authorized capital of Rs 20,00,00,000. Additionally, the board accepted the resignation of M/s. SSRV and Associates as Statutory Auditors, effective immediately, and appointed M/s DEVAM & Associates LLP to the role, pending shareholder approval at the next Annual General Meeting. Mrs. Khushboo Vasudev was also re-appointed as an Independent Director for a second five-year term, also subject to shareholder approval. The Managing Director or Company Secretary will handle the AGM notice and e-voting process, in compliance with SEBI regulations.

Tavexia Lifecare Limited, formerly Sattva Sukun Lifecare Limited, informed the BSE that the Board of Directors meeting scheduled for Friday, September 4, 2026, was adjourned due to unavoidable circumstances and has been rescheduled to Monday, September 7, 2026, at the same venue, with the same agenda.

Tavexia Lifecare Limited, formerly Sattva Sukun Lifecare Limited, will hold a board meeting on Friday, September 4, 2026, to consider the re-appointment of Mrs. Khushboo Vasudev as an Independent Director for a second term of five years from December 31, 2026, subject to shareholder approval, and to approve a proposal for Material Related Party Transactions under section 188 of the Companies Act 2013, also pending shareholder approval.

Tavexia Lifecare Limited, formerly known as Sattva Sukun Lifecare Limited, informed the BSE Limited that the Ministry of Corporate Affairs has approved the change in the company’s name and issued a fresh certificate of incorporation, effective August 14, 2026. The BSE Limited has also approved the application for the name change, and the company will now be known as Tavexia Lifecare Limited.

Sattva Sukun Lifecare Ltd share price ticked higher by 1.32% to Rs 0.77. The Company's net profit tumbled by 77.46% to Rs 0.16 crore, while revenue from operations nosedived 92.47% to Rs 0.64 crore in Q2FY26 over Q1FY26. The market capitalization of Distributors industry group stocks on BSE stood at Rs 899.73 crore, rising 0.58%. It has inched up 1.24% over last one week and softened by 1.69% in last one month while the market capitalization of Sattva Sukun Lifecare Ltd has marginally improved by 2.68% and 11.60% in the same period respectively. Profit before tax (PBT) of Sattva Sukun Lifecare Ltd stood at Rs 0.31 crore in Q2 FY26, crashing by 144.93% year-on-year, and plunging by 64.37% quarter-on-quarter. EBITDA came in at Rs 0 crore, tanking 146.15% YoY and tumbling by 97.09% sequentially. Total expenses saw a steep drop of 93.29% to Rs 1.02 crore in Q2FY26 over Q2FY25. During the quarter, employee benefits expense was at Rs 0.12 crore, tanking by 14.29% YoY. For the TTM ended FY26, revenue from operations witnessed a strong growth of 48.17% to Rs 5.26 crore, while net profit soared by 109.24% to Rs 2.49 crore, compared to previous TTM. EBITDA surged by 96% to Rs 2.85 crore, and PBT jumped 108.50% to Rs 3.19 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 0.53 crore in FY26, as against Rs 2.32 crore in FY25. Sattva Sukun Lifecare Ltd slipped 4.94% in last one year, significantly underperforming the benchmark BSE Sensex which has slipped by 2.94% during the same period.